Dermapharm Holding SE
Industry Group: Pharmaceuticals
Country/Region: Germany
Identifier: ETR:DMP
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals and other healthcare products which drive key revenue, Herbal extracts, and Parallel import business. Branded pharmaceuticals and other healthcare products focus on the development, manufacturing, and marketing of branded pharmaceuticals and other healthcare products. Herbal extracts include the manufacturing of phytopharmaceuticals, nutraceuticals, and cosmetics products. Parallel import brands business operates under the AxiCorp brand.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 321 out of 851
Universe
Global Universe 9090 out of 15104
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Dermapharm Holding SE |
27.6
Medium
|
321 out of 851 |
| Grand Pharmaceutical Group Ltd. |
31
High
|
482 out of 851 |
| Hisamitsu Pharmaceutical Co., Inc. |
33.2
High
|
576 out of 851 |
| Hypera SA |
33.4
High
|
594 out of 851 |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. |
36
High
|
702 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.